Trastuzumab imbotolimod

艾莫曲妥珠单抗

Report date: 2025/02/26 20:00:45

Base Information

Drug NameTrastuzumab imbotolimod

Drug Alias NameBDC-1001Boltbody™ ISAC BDC-1001

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-HER2

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsMetastatic breast cancerSolid tumoursEndometrial Neoplasms +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFranceSpain +[4]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBolt Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesBolt Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsEndometrial NeoplasmsEsophageal Neoplasms

Inactive IndicationsMetastatic breast cancerSolid tumoursColorectal Neoplasms +[5]

Other Information

ATC CodeN/A